you mean this one? ....
RBS Australia rates CUV as Buy (1) - The broker takes the view the company is moving closer to final approval for afamelanotide, which increases natural melanin production.
On its numbers market opportunities in the US and EU could be worth as much as $1.56 per share for the company in net present value terms and so the broker retains its Buy rating.
Target price is $0.78 Current Price is $0.23 Difference:$0.55
who can afford afamelanotide?, page-11
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.50 |
Change
0.130(0.97%) |
Mkt cap ! $666.5M | |||
| Open | High | Low | Value | Volume |
| $13.51 | $13.62 | $13.30 | $1.017M | 75.89K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 271 | $13.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.50 | 886 | 1 |
View Market Depth
| Last trade - 16.10pm 26/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |